DeFi Trial Update Shows Nirogacestat's Efficacy in Desmoid Tumors
Bernd Kasper, MD, PhD, discusses the key efficacy results from the updated analysis of the phase 3 DeFi trial of nirogacestat in desmoid tumors.
Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses key efficacy results from the phase 3 DeFi trial (NCT03785964) of nirogacestat (Ogsiveo) for the treatment of patients with progressing desmoid tumors.
The global, randomized, multicenter, phase 3 trial previously supported the FDA approval of the agent for the treatment of patients with progressing desmoid tumors after nirogacestat reduced the risk of disease progression or death by 71% compared with placebo in patients with desmoid tumors (HR, 0.29; 95% CI, 0.15-0.55; P < .001).1,2 Of the patients treated with nirogacestat (n = 70), the Kaplan-Meier-estimated median progression-free survival (PFS), the primary end point of the study, was not estimated. For patients treated with placebo (n = 72), the median PFS was 15.1 months (95% CI, 8.4-not estimable). The likelihood of being event-free at 1 year was higher among patients treated with nirogacestat vs placebo, at 85% (95% CI, 73%-92%) and 53% (95% CI, 40%-64%), respectively.
An updated analysis of DeFi examined the long-term efficacy and safety of nirogacestat in patients who continued treatment beyond the double-blind phase into an open-label extension. The study focused on evaluating outcomes at 1, 2, 3, and 4-year milestones.
Key findings showed that the drug demonstrated sustained efficacy over time, with the overall response rate increasing from 34% at 1 year to approximately 46% at 4 years. The analysis revealed a deepening of responses over time, with 3 additional partial responses and 3 additional complete responses observed, resulting in a total of 8 complete responses within the analyzed patient population.
There were also no new safety signals identified during the extended treatment period. Further, patient-reported outcomes remained consistent, supporting the long-term tolerability of the drug.
References
FDA approves nirogacestat for desmoid tumors. News release. FDA. November 27, 2023. Accessed March 25, 2025. https://tinyurl.com/mwyyeeeh
Gounder M, Ratan R, Alcindor T, et al. Nirogacestat, a γ-secretase inhibitor for desmoid tumors. N Engl J Med. 2023;388(10):898-912. doi:10.1056/NEJMoa2210140
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
